首页 > 市场调查报告书 > 製药

开发平台分析

市场调查报告书

商品编码

1789394

GLP-1 类似物市场：依药物类型、品牌、用途、给药途径、类型、性别、年龄层、分销管道及地区

Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography

出版日期: 2025年07月08日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

GLP-1 类似物市场规模预计在 2025 年达到 535 亿美元，预计到 2032 年将达到 1,044.4 亿美元，2025 年至 2032 年的复合年增长率为 10.1%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	535亿美元
效能数据	2020-2024	预测期	2025-2032
预测期：2025-2032年复合年增长率：	10.10%	2032年预测	1044.4亿美元

GLP-1类似物市场是糖尿病治疗领域的一个革命性领域，它从根本上改变了第二型糖尿病和肥胖症管理的治疗模式。 GLP-1类似物是天然存在的肠促胰岛素激素GLP-1的合成版本，GLP-1透过刺激胰岛素分泌、抑制升糖素分泌和减缓排放，在维持血糖稳态方面发挥关键作用。这些创新疗法因其双重作用机制：血糖控制和显着减重，已成为治疗的基石。

市场提供各种剂型，包括每日一次、每週一次和长效剂型，以满足不同的患者偏好和治疗通讯协定。主要企业正在大力投资研发，以透过先进的给药系统来提高疗效、减少副作用和改善患者依从性。全球糖尿病盛行率的上升以及人们对肥胖相关併发症认识的不断提高，使GLP-1类似物成为医疗保健提供者的首选治疗方案。这个细分市场持续经历强劲成长，这得益于不断扩大的临床应用，包括降低心血管风险和潜在的神经保护作用，使其成为现代製药业中最具活力和发展最快的领域之一。

市场动态

GLP-1类似物市场受到多个强劲驱动因素的支撑，这些因素支撑着其强劲的成长轨迹。首先是全球第2型糖尿病和肥胖症的盛行率不断上升，目前全球超过5.37亿成年人受其影响，对有效的治疗性介入的需求空前高涨。 GLP-1类似物卓越的疗效，显着降低糖化血红蛋白（HbA1c）水平并显着减轻体重，使其成为优于传统糖尿病药物的治疗选择。此外，越来越多的临床证据支持其心血管保护作用以及在非酒精性脂肪肝病（NAFLD）中的潜在应用，拓宽了治疗领域并推动了市场应用。包括缓释性和创新註射装置在内的药物传递系统技术进步，正在提高患者的便利性和依从性，进一步刺激市场成长。然而，市场也面临着许多限制因素，例如与传统糖尿病药物相比，GLP-1类似物价格高昂，这造成了药物的可及性障碍，尤其是在价格敏感型市场，并且在某些地区保险覆盖范围有限。

噁心、呕吐和腹泻等消化器官系统道副作用会影响患者的依从性和治疗保留率，阻碍市场渗透。肽基生技药品的生产复杂性带来了供应链挑战和成本影响。然而，新兴经济体中尚未开发的市场也蕴藏着巨大的商机，这些地区的糖尿病盛行率正在迅速上升，同时医疗基础设施得到改善，保险覆盖范围不断扩大。 GLP-1 类似物与其他糖尿病药物联合治疗的潜力提供了有利可图的开发机会。此外，正在进行的对阿兹海默症、帕金森氏症和其他代谢紊乱等新适应症的研究可以将 GLP-1 类似物定位为糖尿病管理之外的多功能治疗平台，从而显着扩展潜在市场。

本次调查的主要特点

本报告对全球 GLP-1 类似物市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、业绩和策略等参数，概述了全球 GLP-1 类似物市场的主要企业。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 53.50 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.10%	2032 Value Projection:	USD 104.44 Bn

The glucagon like peptide 1 analogs market represents a revolutionary segment within the diabetes therapeutics landscape, fundamentally transforming treatment paradigms for Type 2 diabetes mellitus and obesity management. GLP-1 analogs are synthetic versions of the naturally occurring incretin hormone GLP-1, which plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These innovative therapeutic agents have emerged as cornerstone treatments due to their dual mechanism of action, offering both glycemic control and significant weight reduction benefits.

The market encompasses various formulations including once-daily, once-weekly, and emerging longer-acting preparations, catering to diverse patient preferences and treatment protocols. Leading pharmaceutical companies have invested heavily in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance through advanced delivery systems. The growing prevalence of diabetes worldwide, coupled with increasing awareness of obesity-related comorbidities, has positioned GLP-1 analogs as preferred therapeutic options among healthcare providers. This market segment continues to witness robust growth driven by expanding clinical applications, including cardiovascular risk reduction and potential neuroprotective effects, making it one of the most dynamic and rapidly evolving sectors in modern pharmaceutical industry.

Market Dynamics

The glucagon like peptide 1 analogs market is propelled by several compelling drivers that underscore its robust growth trajectory. The primary driver is the escalating global prevalence of Type 2 diabetes and obesity, with over 537 million adults currently living with diabetes worldwide, creating an unprecedented demand for effective therapeutic interventions. The superior efficacy profile of GLP-1 analogs, demonstrating significant HbA1c reduction alongside substantial weight loss benefits, positions these agents as preferred treatment options over traditional diabetes medications. Additionally, expanding clinical evidence supporting cardiovascular protective effects and potential applications in non-alcoholic fatty liver disease (NAFLD) broadens the therapeutic scope, driving market adoption. Technological advancements in drug delivery systems, including extended-release formulations and innovative injection devices, enhance patient convenience and adherence, further stimulating market growth. However, the market faces notable restraints, primarily the high cost of GLP-1 analogs compared to conventional diabetes treatments, creating accessibility barriers particularly in price-sensitive markets and limiting insurance coverage in certain regions.

Gastrointestinal side effects, including nausea, vomiting, and diarrhea, can impact patient compliance and treatment continuation, potentially hindering market penetration. Manufacturing complexities associated with peptide-based biologics pose supply chain challenges and cost implications. Nevertheless, significant opportunities emerge from untapped markets in developing economies where diabetes prevalence is rapidly increasing, coupled with improving healthcare infrastructure and expanding insurance coverage. The potential for combination therapies integrating GLP-1 analogs with other diabetes medications presents lucrative development opportunities. Furthermore, ongoing research into novel indications including Alzheimer's disease, Parkinson's disease, and other metabolic disorders could substantially expand the addressable market, positioning GLP-1 analogs as versatile therapeutic platforms beyond diabetes management.

Key Features of the Study

This report provides an in-depth analysis of the global glucagon like peptide 1 analogs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global glucagon like peptide 1 analogs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Daiichi Sankyo, Pfizer, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Intarcia Therapeutics, and Hngzhou Jiuyuan Gene Engineering Co Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global glucagon like peptide 1 analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Semaglutide
- Liraglutide
- Exenatide
- Dulaglutide
- Tirzepatide
- Others
- Linagliptin
- Lixisenatide
Brand Insights (Revenue, USD Bn, 2020 - 2032)
- Saxenda
- Victoza
- Ozempic
- Wegovy
- Rybelsus
- Trulicity Pen
- Zepbound
- Mounjaro
- BYDUREON BCise
- Others
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Type 2 Diabetes Mellitus
- Weight Management (Obesity/Overweight)
- Cardiovascular Risk Reduction
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
Type Insights (Revenue, USD Bn, 2020 - 2032)
- Brand
- Generic
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric/Children
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Boehringer Ingelheim
- Merck & Co.
- Amgen
- GlaxoSmithKline
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Pfizer
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Hngzhou Jiuyuan Gene Engineering Co Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Glucagon Like Peptide 1 Analogs Market, By Drug Type
- Glucagon Like Peptide 1 Analogs Market, By Brand
- Glucagon Like Peptide 1 Analogs Market, By Application
- Glucagon Like Peptide 1 Analogs Market, By Route of Administration
- Glucagon Like Peptide 1 Analogs Market, By Type
- Glucagon Like Peptide 1 Analogs Market, By Gender
- Glucagon Like Peptide 1 Analogs Market, By Age Group
- Glucagon Like Peptide 1 Analogs Market, By Distribution Channel
- Glucagon Like Peptide 1 Analogs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Semaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Liraglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Exenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Dulaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Tirzepatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Linagliptin
Lixisenatide

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Saxenda
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Victoza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ozempic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Wegovy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rybelsus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Trulicity Pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Zepbound
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mounjaro
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
BYDUREON BCise
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Type 2 Diabetes Mellitus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Weight Management (Obesity/Overweight)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pediatric/Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

13. Competitive Landscape

Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intarcia Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hngzhou Jiuyuan Gene Engineering Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

14. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

15. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

GLP-1 类似物市场：依药物类型、品牌、用途、给药途径、类型、性别、年龄层、分销管道及地区

Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography

市场动态

目录

第一章：调查目标和先决条件

第二章市场展望

第三章：市场动态、法规与趋势分析

4. 2020-2032 年全球 GLP-1 类似物市场（依药物类型）

5. 2020 年至 2032 年全球 GLP-1 类似物市场（依品牌）

6. 全球 GLP-1 类似物市场（按应用），2020 年至 2032 年

7. 全球 GLP-1 类似物市场（依给药途径），2020 年至 2032 年

8. 2020 年至 2032 年全球 GLP-1 类似物市场类型

9. 2020-2032 年全球 GLP-1 类似物市场（依性别）

10. 2020-2032 年全球 GLP-1 类似物市场（依年龄层）

11. 全球 GLP-1 类似物市场（依通路），2020 年至 2032 年

12. 全球 GLP-1 类似物市场（按地区），2020 年至 2032 年

第十三章竞争格局

第 14 章分析师建议

第十五章参考文献与调查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

13. Competitive Landscape

14. Analyst Recommendations

15. References and Research Methodology

GLP-1 类似物市场：依药物类型、品牌、用途、给药途径、类型、性别、年龄层、分销管道及地区

Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography

市场动态

目录

第一章：调查目标和先决条件

第二章 市场展望

第三章：市场动态、法规与趋势分析

4. 2020-2032 年全球 GLP-1 类似物市场（依药物类型）

5. 2020 年至 2032 年全球 GLP-1 类似物市场（依品牌）

6. 全球 GLP-1 类似物市场（按应用），2020 年至 2032 年

7. 全球 GLP-1 类似物市场（依给药途径），2020 年至 2032 年

8. 2020 年至 2032 年全球 GLP-1 类似物市场类型

9. 2020-2032 年全球 GLP-1 类似物市场（依性别）

10. 2020-2032 年全球 GLP-1 类似物市场（依年龄层）

11. 全球 GLP-1 类似物市场（依通路），2020 年至 2032 年

12. 全球 GLP-1 类似物市场（按地区），2020 年至 2032 年

第十三章竞争格局

第 14 章分析师建议

第十五章参考文献与调查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

13. Competitive Landscape

14. Analyst Recommendations

15. References and Research Methodology

第二章市场展望